These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15723219)

  • 21. Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo.
    Rittié L; Varani J; Kang S; Voorhees JJ; Fisher GJ
    J Invest Dermatol; 2006 Apr; 126(4):732-9. PubMed ID: 16470170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor mediates stress-induced expression of its ligands in rat gastric epithelial cells.
    Miyazaki Y; Hiraoka S; Tsutsui S; Kitamura S; Shinomura Y; Matsuzawa Y
    Gastroenterology; 2001 Jan; 120(1):108-16. PubMed ID: 11208719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells.
    Ebi M; Kataoka H; Shimura T; Kubota E; Hirata Y; Mizushima T; Mizoshita T; Tanaka M; Mabuchi M; Tsukamoto H; Tanida S; Kamiya T; Higashiyama S; Joh T
    Biochem Biophys Res Commun; 2010 Nov; 402(3):449-54. PubMed ID: 20934403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
    Mimori K; Yamashita K; Ohta M; Yoshinaga K; Ishikawa K; Ishii H; Utsunomiya T; Barnard GF; Inoue H; Mori M
    Clin Cancer Res; 2004 Dec; 10(24):8243-9. PubMed ID: 15623600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells.
    Wiiger MT; Prydz H
    Thromb Haemost; 2004 Jul; 92(1):13-22. PubMed ID: 15213840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
    Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
    Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
    Hirata A; Ogawa S; Kometani T; Kuwano T; Naito S; Kuwano M; Ono M
    Cancer Res; 2002 May; 62(9):2554-60. PubMed ID: 11980649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
    Ornskov D; Nexo E; Sorensen BS
    FEBS J; 2006 Dec; 273(23):5479-89. PubMed ID: 17116246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
    Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
    Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
    Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
    Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated ras-stimulated intestinal epithelial cells.
    Zushi S; Shinomura Y; Kiyohara T; Miyazaki Y; Tsutsui S; Sugimachi M; Higashimoto Y; Kanayama S; Matsuzawa Y
    Int J Cancer; 1997 Dec; 73(6):917-23. PubMed ID: 9399676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor-alpha-induced IL-8 secretion in the human airway epithelial cell line NCI-H292.
    Chokki M; Mitsuhashi H; Kamimura T
    Life Sci; 2006 May; 78(26):3051-7. PubMed ID: 16427093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.
    Faria JAQA; de Andrade C; Goes AM; Rodrigues MA; Gomes DA
    Biochem Biophys Res Commun; 2016 Sep; 478(1):39-45. PubMed ID: 27462018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.